Study of LY4256984 for people with sporadic ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new medicine called LY4256984 for people with sporadic ALS (ALS not caused by a known genetic mutation). The goal is to see if the drug is safe and how it affects the body. It may offer a new treatment option for people recently diagnosed with ALS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of sporadic ALS (not the inherited kind) confirmed by a doctor.
- Your ALS symptoms must have started within the last 2 years.
- Your body mass index (BMI) must be between 18.0 and 35.0 (inclusive).
- You cannot have other serious medical conditions or a history of other neurodegenerative diseases.
- Your liver and kidney function must be within normal limits, and you must not have significant abnormalities on a heart test or spine X-ray.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This study screens people with ALS to see if they might qualify for future gene-targeted treatments. It helps match you to trials that may be a good fit for your genetic type.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This is a follow-up study for people with ALS who have already completed another Eli Lilly ALS treatment trial. Researchers want to continue testing a new drug (LY4256984) in people who tolerated the previous treatment well.
This is a follow-up study for people with ALS (a disease affecting nerve and muscle control) who completed a previous trial called OWAA. Researchers want to test how a new experimental drug called LY4256984 affects the spinal fluid around your brain and spine, which may help them understand if it could slow disease progression.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.